Phase III Study on the Effect of Sitagliptin on Maximal Beta Cell Stimulation
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- FPG,
研究概览
简要总结
The study is designed to investigate the effect of 18 weeks treatment with Sitagliptin 100 mg/day on the insulin secretion capacity of beta cells.
Patients who meet the study enrollment criteria will undergo 2 experiments (see description below); a graded hyperglycemic technique and a meal test, prior to randomization and after a 12-wk double-blind study period. The treatment effect will shed light on the magnitude of the beta cell capacity to increase its mass and function.
详细描述
Study design and duration: This will be an Israeli three center study. Study drug: Sitagliptin 100 mg. The study will be a double blind, randomized two arms parallel group study. The duration of the study will be up to 18 weeks (with 8 visits) for each patient. This will include: a screening period of up to 4 weeks (Visit 1 to visit 2), a 2 week single blind, placebo run-in period (visit 2 to visit 4), and a 12 week placebo controlled, double blind treatment period (visit 4 to visit 8).
Patients with T2DM who have not been treated with an AHA, or who are on AHA monotherapy or low dose oral combination therapy (low dose defined as ≤50% of the maximum labeled dose of each agent), may participate if they meet all enrollment criteria. Patients eligible to be randomized will have a HbA1c ³6.5% and £10% .
Patients who meet the study enrollment criteria will undergo 2 experiments (see description below); a graded hyperglycemic technique and a meal test, prior to randomization (Visit 3 and 4). These experiments will be will be completed after a 12-hour overnight fast. The 2 experiments will be repeated at the conclusion of the 12-wk double-blind study period (Visits 7 and 8).
Efficacy measurements: (1) Glycemic control : FPG, HbA1c, β-cell Function Parameters(Φs, Φd, Φb, Φ, Φob, T), Insulin Secretion Rate (determined from C-peptide deconvolution), 1st and 2nd phase insulin secretion, Insulin response after arginine injection, Insulin sensitivity index, glucose, insulin, C-peptide total and incremental area under the curve.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has T2DM diagnosed within the past 5 years
- •Patient is >18 and <65 years of age
- •Patient is not pregnant, breast feeding and unlikely to conceive
- •Patient understands the study procedures, and agrees to participate in the study by giving written informed consent
- •Patient meets one of the following criteria:
- •Patient is currently not on an AHA and has a Visit 1 HbA1c ≥6.5% and ≤10%. OR
- •Patient is currently on AHA monotherapy or low dose (i.e. ≤50% maximum labeled dose of each agent) oral combination therapy and has a Screening/Visit 1 HbA1c ≥6.5% and ≤9.5%.
- •At visit 2, patient has a HbA1c of ≥6.5% and ≤10%
排除标准
- •Patient has type 1 diabetes mellitus
- •Patient required insulin therapy within 12 weeks of Visit
- •Note: patients who received a brief period of insulin treatment (e.g., several days during a hospitalization) and who are no longer requiring insulin treatment may participate
- •Patient is currently or within 12 weeks of Visit 1 taking a TZD agent as monotherapy or in combination
- •Patient is currently or within 12 weeks of Visit 1 taking Byetta.
- •Patient is on corticosteroids
- •Patient has a history of malignancy ≤5 years prior to signing informed consent, or >5 years without documentation of remission/cure Exception: Adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Melanoma, leukemia, lymphoma and myeloproliferative disorders of any duration are excluded -Patient is on chemotherapy
- •Patient received another investigational drug in the last 12 weeks.
- •Patients with concomitant liver disease and or AST > 3 fold upper limit of normal
- •Patients with kidney disease or CR>1.4 mg/dl
- •Patients with anemia ( Hb <11 gr in male 10 gr in female)
- •Patient with active vascular disease (coronary, peripheral or cerebrovascular)
- •Patient has poorly controlled hypertension defined as systolic blood pressure >160 mm Hg or diastolic >95 mm Hg
- •Proliferative retinopathy
结局指标
主要结局
FPG,
HbA1c,
β-cell Function Parameters(Φs, Φd, Φb, Φ, Φob, T), Insulin Secretion Rate (determined from C-peptide deconvolution), 1st and 2nd phase insulin secretion, Insulin response after arginine injection, Insulin sensitivity index, glucose, insulin,
C-peptide total and incremental area under the curve.
次要结局
未报告次要终点